The Pharmaceutical Benefits Advisory Committee has pointed to the "extremely high cost" as a reason for rejecting a much-anticipated weight-loss therapy. It has also provided advice on extending access to more PBS medicines for people in custodial settings. …
No recommendation for Novo Nordisk's much-anticipated weight loss therapy
December 18, 2023 Latest NewsBioPharma
Latest Video
New Stories
-
CSL unveils US expansion, cementing its position as a global biopharma leader
November 19, 2025 - - Latest News -
Cleo Diagnostics appoints U.S. oncologist as first key opinion leader
November 19, 2025 - - Australian Biotech -
IDT Australia resets strategy as advanced therapies drive new phase of growth
November 19, 2025 - - BioPharma -
Dimerix Phase 3 kidney trial clears seventh safety review
November 19, 2025 - - Australian Biotech -
Prescient secures EU orphan status for PTX-100 for cutaneous T-cell lymphomas
November 19, 2025 - - Australian Biotech -
BCAL advances early cancer detection portfolio as Australian launch looms
November 19, 2025 - - Australian Biotech -
Is this disconnect so entrenched we can no longer recognise the presence of a problem?
November 19, 2025 - - Latest News